← Human Trials & Peer-Reviewed Studies
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial
Plain-language guide to PMID 28097356 (2017): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 683 patients, hyperparathyroidism.
Key Facts
- PMID
- 28097356
- Journal
- JAMA
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Block GA et al. (15 authors)
- DOI
- 10.1001/jama.2016.19468
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.
Control is suboptimal in the majority of patients receiving hemodialysis.
Who Took Part
According to the abstract, 683 patients were involved.
PubMed indexes the participants as middle-aged adults, both men and women.
Patients were enrolled from August 2013 to May 2014, with end of follow-up in January 2015.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.
Some patients received a placebo instead of Parathyroid Hormone (PTH 1-84), giving a reference point.
A time span of 26 weeks appears in the methods.
Etelcalcetide intravenously and oral placebo (n = 340) or oral cinacalcet and IV placebo (n = 343) for 26 weeks.
The IV study drug was administered 3 times weekly with hemodialysis; the oral study drug was administered daily.
What Was Measured
PubMed files the paper under topics including Biomarkers, Calcimimetic Agents, Calcium, Cinacalcet, Fibroblast Growth Factor-23, Fibroblast Growth Factors and Hyperparathyroidism, Secondary.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 683 patients in people with hyperparathyroidism over 26 weeks.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2017 (JAMA), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.